Riskpilot← Back to searchSign inGet full accessAllarity Therapeutics A/S
A/SIn liquidationCVR 28106351Venlighedsvej 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20046 employees
Revenue 2024
DKK 0
EBITDA margin
—
-389% vs 2023
Equity ratio
—
Financial strength
Net profit 2024
DKK -83K
+80% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK -81K | -389% |
| Net profit | DKK -83K | +80% |
| Total assets | DKK 78K | -81% |
| Equity | DKK 0 | -100% |
| Employees | 6 | — |
Legal name
Allarity Therapeutics A/S
CVR number
28106351
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9. september 2004
Share capital
DKK 1.389.478
Employees
6 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Venlighedsvej 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 403.834 | 0 | 0 | 0 |
| Staff expenses | -22.610 | -7.469 | -0 | -0 | -0 |
| EBITDA | -58.958 | 396.365 | -583 | 28 | -81 |
| Depreciation & amort. | -1.059 | -115 | -0 | -0 | -0 |
| EBIT | -60.017 | 396.250 | -583 | 28 | -81 |
| Net financials | 932 | 169.782 | -14.029 | -434 | -2 |
| Profit before tax | -59.085 | 566.032 | -14.612 | -406 | -83 |
| Tax | -11.379 | 274 | -0 | -0 | -0 |
| Net profit | -47.706 | 565.758 | -14.612 | -406 | -83 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 176.922 | 32.027 | 889 | 416 | 78 |
| Equity | 140.583 | 31.307 | 488 | 83 | 0 |
| Long-term debt | 1.615 | 0 | 0 | 0 | 0 |
| Short-term debt | 34.724 | 720 | 401 | 333 | 78 |
| Total debt | 36.339 | 720 | 401 | 333 | 78 |
EBITDA margin
-8100000.0%
This company
15.8%
Market median
-51265923% vs market
20202024
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20202024
Return on equity
-8300000.0%
This company
18.4%
Market median
-45108796% vs market
20202024
Net profit margin
-8300000.0%
This company
8.1%
Market median
-102469236% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
77999.00×
This company
0.62×
Market median
-12580384% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (9) | ||
LL Unofficial title | Unofficial title | 2022 – 2025 |
HK Management | Management | 2019 – 2020 |
JE Management | Management | 2020 – 2022 |
SR Chief Executive Officer | Chief Executive Officer | 2019 – 2022 |
JA Chief Executive Officer | Chief Executive Officer | 2010 – 2012 |
PB Chief Executive Officer | Chief Executive Officer | 2012 – 2019 |
JD Chief Executive Officer | Chief Executive Officer | 2006 – 2010 |
JG Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
SM Management | Management | 2004 – 2006 |
| Name | Role | Member since |
|---|---|---|
| Former (10) | ||
| Chairman | 2012 – 2015 | |
| Board of Directors | 2017 – 2018 | |
| Chairman | 2018 – 2022 | |
| Board of Directors | 2005 – 2018 | |
| Board of Directors | 2018 – 2020 | |
| Deputy Chairman | 2018 – 2020 | |
| Board of Directors | 2014 – 2020 | |
| Board of Directors | 2020 – 2022 | |
| Chairman | 2004 – 2006 | |
| Board of Directors | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 20–24.99% | 20–24.99% | 2020 | |
| Company | 10–14.99% | 0% | 2013 | |
| Company | 5–9.99% | 5–9.99% | 2013 | |
| Company | 5–9.99% | 5–9.99% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Allarity Therapeutics A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Lüthjohan | Unofficial title | 0 companies |
| Henrik Kristian Moltke | Management | 0 companies |
| Jens Erik Knudsen | Management | 0 companies |
| Stefano Roberto Carchedi | Chief Executive Officer | 0 companies |
| Jon Askaa | Chief Executive Officer | 0 companies |
| Peter Buhl | Chief Executive Officer | 0 companies |
| Jesper Drejet | Chief Executive Officer | 0 companies |
| James G. Cullem | Chief Executive Officer | 0 companies |
| Steen Meier Knudsen | Management | 0 companies |
| Jørgen Søberg Petersen | Chairman | 0 companies |
| Jørgen Vilhelm Løvenørn Bardenfleth | Board of Directors | 0 companies |
| Duncan Moore | Chairman | 0 companies |
| Niels Johansen | Board of Directors | 0 companies |
| Carani Sanjeevi | Board of Directors | 0 companies |
| Frank Knudsen | Deputy Chairman | 0 companies |
| Gunnar Magnus Severus Modée Persson | Board of Directors | 0 companies |
| Gail Maderis | Board of Directors | 0 companies |
| Carsten Schou | Chairman | 0 companies |
| Søren Gade Jensen | Board of Directors | 0 companies |